PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Phenotype | |cognitive deficits |
| Sentences | 145 |
| PubMedID- 23322976 | The pathophysiology underlying the cognitive deficits often associated with schizophrenia may be distinct from that causing some of the core clinical features (3). |
| PubMedID- 25432636 | Background: neurocognitive deficits in schizophrenia (sz) are established and the consortium on the genetics of schizophrenia (cogs) investigated such measures as endophenotypes in family-based (cogs-1) and case-control (cogs-2) studies. |
| PubMedID- 24526625 | The etiologic and phenomenological complexity of neurocognitive deficits in schizophrenia may be better served by psychopharmacological agents that (i) target neurotransmitter systems proximal in the causal chain to neurocognitive deficits; (ii) enhance distal survival processes in the central nervous system-neurogenesis, neuronal growth, synaptogenesis, and connectivity; and (iii) counteract the negative effects of aberrant neurodevelopment in schizophrenia, such as neuroinflammation and oxidative stress. |
| PubMedID- 24396009 | Results suggest that vulnerability for schizophrenia is associated with neurocognitive deficits in tom and the degree of deficit is related to day-to-day social functioning. |
| PubMedID- 22906530 | cognitive deficits associated with schizophrenia (cds) are implicated as a core symptom cluster of the disease and are associated with poor daily life functioning. |
| PubMedID- 22096516 | The alpha7 nicotinic acetylcholine receptor (nachr) is a potential target for the treatment of cognitive deficits in patients with schizophrenia, adhd and alzheimer's disease. |
| PubMedID- 21702128 | Therefore, a number of new therapeutic drugs for cognitive deficits in schizophrenia are currently being developed around the world. |
| PubMedID- 26359226 | Rationale: new pharmacological treatments for the cognitive deficits in schizophrenia are needed. |
| PubMedID- 25774979 | Symptoms of anxiety in schizophrenia are associated with cognitive deficits, a greater risk of relapse, poorer quality of life, and an increased risk of suicide [6]. |
| PubMedID- 26106146 | Dysregulation of d1r has been related to cognitive deficits in schizophrenia, and there is a need for new, lower-affinity d1r agonists that may better mimic endogenous da to enhance mental representations and improve cognition. |
| PubMedID- 25103208 | It is not clear whether cognitive deficits associated with schizophrenia remain as strong predictors of function in older and younger individuals. |
| PubMedID- 20573264 | Background: cognitive deficits in schizophrenia are associated with psychosocial deficits that are primarily responsible for the poor long-term outcome of this disease. |
| PubMedID- 20584553 | This study investigates whether social cognitive deficits found in patients with schizophrenia are specific to social threat stimuli, and whether the deficits increase across the delusion spectrum from a subclinical sample to clinical manifestation. |
| PubMedID- 25803852 | Lastly, we suggest that t-817ma could be a new candidate for the treatment of negative symptoms and cognitive deficits associated with schizophrenia and autism. |
| PubMedID- 22745912 | Due to cognitive deficits, individuals with schizophrenia often struggle to transport skills and lessons from the treatment environment to their day-to-day lives [36]. |
| PubMedID- 25959604 | Conclusion: the arcs may be sensitive to the cognitive deficits in outpatients with schizophrenia and an indicator of functional outcomes in this population. |
| PubMedID- 24656901 | Cognitive remediation is the best available tool to treat cognitive deficits in schizophrenia and has evidence of biological validity; however results are still heterogeneous and significant predictors are lacking. |
| PubMedID- 26233432 | Smaller than expected cognitive deficits in schizophrenia patients from the population-representative abc catchment cohort. |
| PubMedID- 26433217 | We analyzed the effects of 10-hz rtms to the left dlpfc on cognitive deficits in schizophrenia in a large-scale and multicenter, sham-controlled study. |
| PubMedID- 23027611 | cognitive deficits in schizophrenia severely compromise quality of life and are poorly controlled by current antipsychotics. |
| PubMedID- 23104864 | Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study. |
| PubMedID- 23430145 | cognitive deficits in schizophrenia are pervasive, severe, and largely independent of the positive and negative symptoms of the illness. |
| PubMedID- 22695257 | Cognitive remediation training has been shown to improve both cognitive and social cognitive deficits in people with schizophrenia, but the mechanisms that support this behavioral improvement are largely unknown. |
| PubMedID- 25566009 | cognitive deficits in schizophrenia and other neuropsychiatric disorders: convergence of preclinical and clinical evidence. |
| PubMedID- 21808609 | The cognitive deficits associated with schizophrenia are commonly believed to arise from the abnormal temporal integration of information, however a quantitative approach to assess network coordination is lacking. |
| PubMedID- 21924537 | In this study, we examined antisaccade performance in patients and relatives, and sought to establish whether antisaccade measures could differentiate between two patients clusters identified in the western australian family study of schizophrenia with either pervasive cognitive deficits (cd) or cognitively spared (cs). |
| PubMedID- 24179753 | schizophrenia (sz) is associated with cognitive deficits that represent a core feature of the disorder and are primary predictors of impaired long-term functional outcome. |
| PubMedID- 25750798 | Cognitive remediation therapy (crt) has been proved to improve cognitive deficits in schizophrenia and to enhance functional outcomes of classical rehabilitation. |
| PubMedID- 24583905 | To date, many studies have suggested that cognitive deficits in patients with schizophrenia are stable over time, regardless of symptomatic fluctuations.34 a meta-analysis of 53 longitudinal studies found that patients with schizophrenia show significant improvements in most cognitive tasks,35 although they may not improve with time as much as controls.36 however, previous studies tend not to focus on general population samples and usually do not follow up patients over periods as long as the 9-year follow-up employed in our study. |
| PubMedID- 23172002 | The deficits reported typically fall between 1 and 2 standard deviations below the mean of healthy controls.88,89 cognitive deficits in patients with schizophrenia are associated with inability to function in the community90 and, as a result, have been the focus of specific clinical interventions.91 measures of cognitive functioning have been shown to correlate with measures of brain structure in patients with schizophrenia and healthy controls.92–95 if progressive brain tissue loss occurs over the course of schizophrenia, one might predict that this would be accompanied by progressive deterioration in cognitive functioning. |
| PubMedID- 20300465 | Neurocognitive deficits in schizophrenia (sz) are thought to be stable trait markers that predate the illness and manifest in relatives of patients. |
| PubMedID- 23115554 | Cannabis use characterizes a subgroup of schizophrenia patients with less cognitive deficits. |
| PubMedID- 21904685 | Therefore, cognitive deficits in schizophrenia may result from a gaba synapse dysfunction that disturbs neural synchrony. |
| PubMedID- 22705396 | cognitive deficits in schizophrenia are critically important predictors of long-term psychosocial outcome and are not significantly ameliorated by currently available medications. |
| PubMedID- 24747179 | cognitive deficits in schizophrenia (sz) reflect maturational disruptions within a neural system that includes the ventral hippocampus (vh), nucleus accumbens (nac), basal forebrain, and prefrontal cortex (pfc). |
| PubMedID- 22559128 | cognitive deficits in schizophrenia are increasingly accepted as core features of this disorder that play a role as vulnerability indicators, as enduring abnormalities during clinical remission, and as critical rate-limiting factors in functional recovery. |
| PubMedID- 20083164 | Based on nmda hypofunction hypothesis for negative symptoms and cognitive deficits in schizophrenia, mk-801-induced animal models of schizophrenia may help us understand the different effects between typical and atypical antipsychotics. |
| PubMedID- 20705091 | cognitive deficits in schizophrenia remain an unmet clinical need. |
| PubMedID- 25450228 | cognitive deficits lie upstream of the liability for schizophrenia with about a quarter of the variance in liability to schizophrenia explained by variation in cognitive function. |
| PubMedID- 20195567 | Pharmacological treatment of cognitive deficits in schizophrenia is still a challenge. |
| PubMedID- 20970118 | Background: cognitive deficits in schizophrenia may be related to glutamatergic dysfunction, but in vivo measurement of glutamate metabolism has been challenging. |
| PubMedID- 24391807 | The temporal gray matter volume abnormalities found in our study likely contributes to cognitive deficits in patients with untreated schizophrenia as reported in the literature. |
| PubMedID- 20195566 | Standards for the reliable evaluation of neurocognitive deficits in schizophrenia have been put forward by the matrics initiative (measurement and treatment research to improve cognition in schizophrenia). |
| PubMedID- 25510904 | Previous research has suggested that the pattern and severity of cognitive deficits in people with severe chronic schizophrenia is similar to that observed in behavioural variant frontotemporal dementia (bvftd). |
| PubMedID- 22715980 | In order to improve the methodological quality of the studies performed in the field of cognitive deficits of patients with schizophrenia, various factors should be taken into account and better managed in designing future studies. |